Colposcope developer Dysis has closed a series B round featuring existing investor Lundbeckfonden Ventures that will fund growth and R&D.
UK-based cancer screening technology developer Dysis Medical closed an £18m ($24m) series B round today featuring Lundbeckfonden Ventures, the strategic investment arm of pharmaceutical firm Lundbeck.
The company has not specified whether Lundbeckfonden Ventures, which invested as an existing backer, supplied the full amount or participated alongside other investors.
Dysis Medical has developed a colposcope that is used for cervical cancer screening, and recently released the latest version of the device.
The company has also been overseeing large-scale trials for…